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Abstract
Background: Cardiovascular comorbidity in COPD is common and contributes to increased mortality. A few
population-based studies indicate that ischemic electrocardiogram (ECG)-changes are more prevalent in COPD,
while others do not. The aim of the present study was to estimate the presence of ischemic heart disease (IHD) in a
population-based COPD-cohort in comparison with subjects without COPD.
Methods: All subjects with obstructive lung function (COPD, n = 993) were identified together with age- and
sex-matched controls (non-COPD, n = 993) from population-based cohorts examined in 2002–04. In 2005, data from
structured interview, spirometry and ECG were collected from 1625 subjects. COPD was classified into GOLD 1–4
after post-bronchodilator spirometry. Ischemic ECG-changes, based on Minnesota-coding, were classified according
to the Whitehall criteria into probable and possible IHD.
Results: Self-reported IHD was equally common in COPD and non-COPD, and so were probable and possible
ischemic ECG-changes according to Whitehall. After excluding subjects with restrictive spirometric pattern from
the non-COPD-group, similar comparison with regard to presence of IHD performed between those with COPD
and those with normal lung-function did neither show any differences. There was a significant association between
self-reported IHD (p = 0.007) as well as probable ischemic ECG-changes (p = 0.042), and increasing GOLD stage. In COPD
there was a significant association between level of FEV1 percent of predicted and self-reported as well as probable
ischemic ECG-changes, and this association persisted for self-reported IHD also after adjustment for sex and age.
Conclusion: In this population-based study, self-reported IHD and probable ischemic ECG-changes were associated with
COPD disease severity assessed by spirometry.
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Background
The prevalence of chronic obstructive pulmonary disease
(COPD) is approximately 10 %, and there is still a sig-
nificant under-diagnosis with up to 80 % of the cases
not yet identified by healthcare [1–3]. COPD is associ-
ated with several comorbidities whereof cardiovascular
disease (CVD) is the most common [4] and both of
these conditions are among the leading causes of death
worldwide [5, 6]. The associations between COPD and
CVD are complex; besides sharing common risk factors
such as smoking and aging [7, 8], also systemic inflam-
mation is suggested as a possible link between the con-
ditions [9, 10].
Among cardiovascular diseases, ischemic heart disease
(IHD) is of particular interest. . According to the WHO,
globally IHD was responsible for 7.5 million out of the
total 17.4 million CVD deaths in 2012. Hospital-based
studies have shown that IHD is common among subjects
with COPD [11, 12] and there is an increased risk for
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death after a myocardial infarction among those with
COPD compared to those without [13–15]. A recently
published review clearly shows that IHD worsens the
disease progress as well as prognosis among subjects
with COPD [5, 6, 16]. However, the under-diagnosis of
COPD most probably contributes to an underestimation
of the real impact of IHD among subjects with COPD in
the general population. Simple diagnostics signs of IHD
in COPD, such as ischemic findings on electrocardio-
gram (ECG), have hardly been evaluated in population-
based studies.
The aim of this population-based study was to esti-
mate the prevalence of self-reported ischemic heart dis-
ease and ischemic ECG changes among subjects with
COPD in comparison with subjects without obstructive
lung function impairment, divided into normal lung
function and restrictive pattern. Our hypothesis was that
the prevalence of IHD would be higher among subjects
with COPD compared with subjects with normal lung
function and that the prevalence of IHD would increase
with COPD disease severity, as assessed by spirometry.
Methods
Study population
Four population-based cohorts from the Obstructive
Lung Disease in Northern Sweden (OLIN) studies were
re-examined during 2002–2004. All subjects with ob-
structive lung function impairment (COPD) were
identified (n = 993) together with an age- and sex-
matched reference population without obstructive lung
function impairment. The study population (n = 1986) has
since 2005 been invited to annual examinations with
a basic program including spirometry and structured
interview [17].
This study is based on data collected in 2005 when
ECG recordings were performed in addition to the
basic program. In total, 1641 participated whereof
1625 had complete data on spirometry, structured
interview and ECG. The structured interview ques-
tionnaire included questions validated in national and
international studies [18–21]. The Regional Ethics
Committee at Umeå University approved the study
(approval number 04-045 M), which was carried out
according to the declaration of Helsinki. Written informed
consent for participation in the study was obtained from
all participants.
Definitions
Self-reported IHD was based on data from the struc-
tured interview, and was defined as any history of angina
pectoris, myocardial infarction, coronary artery bypass
surgery (CABG) or percutaneous coronary intervention.
Hypertension was defined by affirmative answer to the
question “Do you have high blood pressure?” Body mass
index (BMI) was calculated and classified in four groups
(underweight <20, normal 20–24.9, overweight ≥ 25–
29.9 and obesity ≥ 30 kg/m2). Smoking habits were clas-
sified as non-smoker, ex-smoker (stopped since at least
12 months) and smokers, as well as by pack years.
Electrocardiogram
Standard twelve-lead ECG’s were recorded before spir-
ometry, on subjects in the supine position and after suf-
ficient rest. Two independent physicians analyzed all
ECG recordings according to the Minnesota code (MC)
and both of them were blinded to COPD status and spir-
ometry values. ECG-based IHD was defined in accord-
ance to the Whitehall criteria as probable IHD; major
Q/QS wave (MC 1.1–1.2) and left bundle branch block
(LBBB) (MC 7.1.1). Possible IHD was defined as minor
Q/QS wave (MC 1.3), ST segment depression (MC
4.1–4.3), and T wave items (MC 5.1–5.3) [22].
Lung function tests
Lung function test was performed in accordance with
the American Thoracic Society guidelines [23], following
ECG registration, using a dry volume spirometer, the
Vicatest 5 (Gebr. Mijnhardt B.V., Odijk, Netherlands).
Vital capacity (VC) was defined as the highest value of
forced vital capacity (FVC) and slow vital capacity (SVC)
pre- or post- reversibility test. Reversibility test was per-
formed with Ventoline® 4x0.2 mg if FEV1/VC <0.70 or if
FEV1 < 80 % of predicted value. COPD was defined as
FEV1/VC <0.70 using the best values of VC and FEV1
pre- or post-reversibility test. Severity of airflow limita-
tion in COPD was classified according to the Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD)
document; GOLD 1–4 based on FEV1 % predicted [24].
The OLIN reference values, based on healthy non-
smokers, were applied [25, 26].
The reference population without obstructive lung
function impairment, defined as FEV1/VC ≥0.70, was
further divided into subjects with normal lung function
(NLF), FEV1/VC ≥0.70 and VC >80 %, and subjects with
restrictive pattern on dynamic spirometry defined as
FEV1/VC ≥0.70 and VC <80 % of predicted.
Statistics
Statistical calculations were performed using the Statis-
tical Package for the Social Sciences (SPSS) software ver-
sion 21.0 (IBM, Armonk, NY, USA). Missing data on
smoking habits and self-reported cardiovascular disease
in a total of 4 subjects were collected from data from
the previous and/or following year’s examinations. The
chi-square test was used for categorical variables and
bivariate comparisons. Mantel-Haenszel test for trend
and Fischer’s exact test was used where appropriate.
Independent sample t-test and ANOVA were used to
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compare means. Association between the continuous
variable FEV1 percent of predicted and self-reported
IHD respectively probable and possible ischemic ECG
changes according to Whitehall was analyzed by bivari-
ate logistic regression with each of the IHD variables as
dependent variable. Analyses were also performed in
similar models adjusting for age and sex. P-values <0.05
were considered statistically significant.
A cross-sectional analysis of COPD and non-obstructive
lung function based on spirometry in 2005 was performed.
A further analysis was performed in which the subjects
had to fulfill the spirometric criteria of COPD vs. non-
COPD not only in 2005 but also at baseline, i.e. at recruit-
ment in 2002–04 and defined as “stable COPD” and
“stable non-COPD”. Those with non-COPD were further
divided into restrictive pattern and NLF.
Results
Characteristics of the study population in 2005
Among all subjects with complete data on spirometry,
interview and ECG in 2005, 634 subjects out of 1625
fulfilled the spirometric criteria of COPD. Basic charac-
teristics are presented in Additional file 1. The burden
of tobacco smoking, assessed as smoking habits as
well as pack years, was significantly higher among
COPD-subjects.
There was no significant difference in the prevalence
of self-reported IHD when comparing non-COPD and
COPD, although myocardial infarction was significantly
more common among COPD-subjects and CABG was
more common among non-COPD-subjects. Ischemic ECG
changes, analyzed separately or categorized according to
Whitehall, were similarly common in non-COPD and
COPD (Additional file 2).
Characteristics of stable non-COPD and stable COPD
Comparing subjects with normal lung function and subjects
with restrictive pattern
Among subjects classified as non-COPD, FEV1/VC
≥0.70, both at baseline and in 2005 (n = 757), 145 sub-
jects had a restrictive pattern on dynamic spirometry.
Subjects with restrictive pattern had higher BMI and
higher prevalence of diabetes, hypertension, angina,
myocardial infarction and arrhythmias compared to sub-
jects with NLF (Table 1).
Comparing subjects with normal lung function and subjects
with COPD
Basic characteristics comparing subjects with FEV1/VC
ratio <0.70 both at baseline and in 2005 (n = 576) and
subjects with NLF at both occasions (n = 612) are given
in Table 1. Subjects with COPD were older, had a lower
mean BMI, and the burden of tobacco smoking was
higher considering both current smoking and pack years
(Table 1). The distribution of COPD by GOLD classifica-
tion was: GOLD 1, n = 221 (38.4 %), GOLD 2, n = 308
(53.5 %) and GOLD 3–4, n = 47 (8.2 %).
The prevalence of self-reported IHD was 16.1 %
among COPD and 12.6 % among subjects with NLF
(p = 0.08). Myocardial infarction was significantly more
common among those with COPD compared with NLF
(Table 1).
Ischemic ECG findings
Comparing subjects with normal lung function and subjects
with COPD
The prevalence of ischemic ECG changes, defined as Q/QS
wave, ST segment depression, T wave items and left bundle
branch block, was similar among subjects with COPD and
NLF, also when ischemic ECG changes were divided into
major, intermediate and minor (Table 2).
When ischemic ECG changes were analysed in groups
according to the Whitehall criteria, “any IHD” had simi-
lar prevalence among subjects with NLF and COPD,
22.9 % and 24.7 % respectively. The subgroups “probable
IHD” and “possible IHD” were also equally prevalent
among subjects with COPD and subjects with NLF
(Table 2).
Ischemic heart disease in relation to COPD severity
The prevalence of self-reported IHD was higher in
GOLD 2 compared with in subjects with NLF (Fig. 1a),
and the test for trend NLF – GOLD 3–4 was significant
(p = 0.007). When comparing the prevalence of ischemic
ECG-changes in each of the GOLD stages with the
prevalence among those with NLF, there were no differ-
ences within any of the Whitehall groups (Fig. 1b, c).
Test for trend in NLF – GOLD 3–4 was significant in
subjects with Whitehall probable IHD (p = 0.042), but
not among Whitehall possible IHD (p = 0.355).
In a logistic regression analysis, FEV1 percent of pre-
dicted value was significantly associated with self-
reported IHD and probable ischemic ECG-changes ac-
cording to Whitehall, but not possible ischemic ECG
changes according to Whitehall (Table 1). When adjust-
ing for age and sex, the association between FEV1 per-
cent of predicted value and self-reported IHD persisted,
while the association with ischemic ECG-changes corre-
sponding to Whitehall probable IHD was lost (Table 3).
Discussion
In this cross sectional population based study, self-
reported as well as ECG changes of ischemic heart
disease (IHD) according to Whitehall were equally preva-
lent among subjects with COPD and those with normal
lung function (NLF). There was a significant association
between increasing presence of self-reported IHD as well
as probable ECG changes of IHD, according to the
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Whitehall criteria, in relation to COPD disease severity,
both classified according to GOLD stage as well as
assessed as FEV1 percent of predicted. The significant re-
lationship between FEV1 percent of predicted and self-
reported IHD but not probable ECG-findings remained
after adjustment for age and sex.
According to a recent review, the prevalence of coron-
ary heart disease (CHD) in different COPD populations
varies between 4.7 % and up to 60 % [27]. Since the re-
cruitment of study population, as well as the definitions
of CHD and COPD, vary between the studies, it is diffi-
cult to compare the results. In a Danish population-
based study [28], the prevalence of IHD was 8.6 % in
non-COPD and increased in COPD by GOLD stage 1, 2
and 3–4; 12.1 %, 14.9 % and 13.7 % respectively; the cor-
responding prevalences of Q-wave (major +minor) were
2.7 % in non-COPD, and 3.3 %, 6.2 % and 6.9 % by
GOLD stages. Overall, self-reported heart disease and
presence of corresponding ECG-findings were markedly
more common in our study compared with in the
Danish survey. One possible explanation for the ob-
served difference is that although the COPD classifica-
tion in the Danish study was based on spirometry, they
used pre-bronchodilator values, i.e. not following current
guidelines recommending post-bronchodilator spirom-
etry for the diagnosis of COPD. Other studies have
shown that the use of pre-bronchodilator spirometry
misclassify up to 27 % of non-obstructive subjects as ob-
structive, which might contribute to the lower IHD
prevalence [29]. Further, the Danish study was a close to
25-year follow-up of the large-scale Copenhagen City
Heart study (with the addition of a smaller random sam-
ple of younger adults) and a healthy survivor effect can
thus be expected to have affected the results. In a
population-based study using the Burden of Obstructive
Lung Disease (BOLD) survey, close to 100 cases of COPD
were identified based on post-bronchodilator spirometry
and they found no increased risk for self-reported
Table 1 Basic characteristics. Comparing subjects with normal lung function (NLF) vs. restrictive pattern and normal lung function
vs. COPD. Analyses were performed among subjects “stable non-COPD” (NLF and restrictive pattern) and “stable COPD); at baseline
and in 2005 (significant values in bold)
Categories Variables NLF n = 612 Restrictive pattern n = 145 Pc COPD n = 576 Pd
Sex
Women, n (%) 292 (47.7) 60 (41.4) 0.17 243 (42.2) 0.06
Age
Mean (SD) 64.8 (11.0) 68.6 (10.1) <0.001 66.6 (10.6) 0.004
BMI
Mean (SD) 27.1 (4.0) 28.4 (4.4) 0.001 26.3 (4.1) 0.001
Underweight <20, n (%) 6 (1.0) 4 (2.8) 22 (3.8)
Normal 20–24.9, n (%) 194 (31.7) 27 (18.8) 204 (35.4)
Overweight 25–29.9, n (%) 290 (47.4) 68 (47.2) 259 (45.0)
Obese ≥30, n (%) 122 (19.9) 45 (31.3) 91 (15.8)
Smoking habits
Pack years, mean (SD) 6.5 (10.3) 6.8 (11.3) 0.74 17.0 (16.2) <0.001
Current smoker, n (%) 71 (11.6) 13 (9.0) 207 (35.9)
Ex smoker, n (%) 234 (38.2) 52 (35.9) 241 (41.8)
Non smoker, n (%) 307 (50.2) 80 (55.2) 128 (22.2)
Comorbiditiesa
Diabetes, n (%) 47 (7.7) 26 (17.9) <0.001 49 (8.5) 0.60
Hypertension, n (%) 197 (32.2) 69 (47.6) 0.001 198 (34.4) 0.42
Angina pectoris, n (%) 67 (10.9) 27 (18.6) 0.01 70 (12.2) 0.521
Myocardial infarction, n (%) 14 (2.3) 12 (8.3) 0.001 32 (5.6) 0.004
CABG, n (%) 18 (2.9) 7 (4.8) 0.25 10 (1.7) 0.17
PCI, n (%) 8 (1.3) 5 (3.4) 0.07 8 (1.4) 0.90
Arrhythmias, n (%) 44 (7.2) 20 (13.8) 0.01 46 (8.0) 0.60
Reported IHDb, n (%) 77 (12.6) 32 (22.1) 0.005 93 (16.1) 0.08
aBased on interview data. bSelf-reported IHD, includes any of angina pectoris, myocardial infarction, CABG and PCI
Pc comparison between normal lung function and restrictive pattern Pd comparison between normal lung function and COPD
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cardiovascular disease or hypertension in either of the
GOLD-stages [30]. In general, population based data on
CHD among subjects with COPD identified by post-
bronchodilator spirometry is mainly self-reported, and
other clinical findings of CHD, such as ECG-changes, have
rarely been evaluated.
A population-based COPD-cohort, such as in our
study, will include a majority of subjects with GOLD 1
and 2 and only a low number of subjects with GOLD 3–
4 [1]. Self-reported IHD as well as ischemic ECG-
findings according to the Whitehall criteria clearly in-
creased by GOLD stage and were considerably more
common in GOLD 3–4 than among subjects with mild
COPD. Even though our study include a large COPD-
cohort, almost comparable to that of the National
Health and Nutrition Examination Survey (NHANES) I
[31], the distribution of GOLD stages contributes to a
lack of power to show statistical significance due to the
small proportion of severe/very severe COPD in a popu-
lation based study, as also demonstrated by the quite
large confidence intervals in Fig. 1. However, each of the
GOLD stages include rather wide ranges of FEV1 % pre-
dicted, and the continuous variable FEV1 % predicted
may be useful when it comes to evaluating events in re-
lation to disease severity. The found positive associations
between level of FEV1 among COPD-subjects and self-
reported IHD as well as probable ischemic ECG-changes
according to the Whitehall criteria, thus further support
a relationship between IHD and COPD disease severity.
Interpretation of the results is that higher FEV1 is
protective, consequently, the presence of IHD increase
the lower FEV1 is, i.e. by increasing COPD disease sever-
ity. Furthermore, the observed high prevalence of ische-
mic ECG-changes in more severe COPD disease is
comparable with findings from studies using hospitals
records including severe stages of COPD [11, 12, 32].
It has also been observed that subjects with COPD
have increased arterial stiffness [33], which is considered
a marker of early atherosclerosis and a risk factor for de-
velopment of CVD. In a recent review it was even sug-
gested that measurements of arterial stiffness should be
included in routine health care to assess the risk for
CVD among subjects with COPD [34]. We have previ-
ously shown that central arterial stiffness is higher in
GOLD 3–4 than in non-COPD [35] also in a population
based study, which is in line with the current findings of
IHD being most prevalent in GOLD 3–4. The clinical
implication may be that not only non-invasive measure-
ments of arterial stiffness, but also ECG may be of value
when evaluating risk for and presence of cardiovascular
disease when diagnosing subjects with COPD. The
underlying pathological mechanism by concomitant
COPD and IHD is, however, not fully understood, but
may be related to systemic inflammation and endothelial
dysfunction [5, 6, 16], and in addition high on-treatment
platelet reactivity has been discussed as reason for the
observed worsened prognosis among subject with con-
comitant COPD and IHD [5, 6, 36].
The original design of the study defined cases and sex
and age-matched controls based on spirometry (COPD
Table 2 Ischemic ECG changes comparing subjects with normal lung function and COPD
NLF n = 612 COPD n = 576 P
Ischemic ECG changes
Q-Waves Any, n (%) 49 (8.7) 48 (8.3) 0.64
Major Q/QS, n (%) 20 (3.4) 24 (4.2) 0.42
Minor Q/QS, n (%) 29 (4.9) 24 (4.2) 0.66
ST-segment depressions Any, n (%) 39 (6.4) 33 (5.7) 0.23
Major, n (%) 4 (0.7) 4 (0.7) 0.94
Intermediate, n (%) 20 (3.3) 18 (3.1) 0.88
Minor, n (%) 15 (2.5) 11 (1.9) 0.52
T- wave items Any, n (%) 98 (16.0) 100 (17.4) 0.53
Major, n (%) 2 (0.4) 1 (0.2) 1.00
Intermediate, n (%) 44 (7.9) 45 (8.7) 0.64
Minor, n (%) 52 (9.2) 54 (9.4) 0.56
Bundle branch block LBBBa, n (%) 10 (1.9) 11 (2.3) 0.68
Whitehall criteria
Ischemic heart disease Any, n (%) 140 (22.9) 142 (24.7) 0.47
Probableb, n (%) 27 (5.4) 35 (6.1) 0.19
Possiblec, n (%) 113 (19.3) 107 (18.6) 0.85
aLeft bundle branch block. bIncluding Major Q/QS and LBBB. cIncluding Minor Q/QS, any ST-segment depression and any T-wave item
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Fig. 1 Ischemic heart disease categorized as (a) Self-reported IHD and (b) Ischemic ECG changes according to Minnesota coding categorized as
probable Whitehall criteria and (c) Possible Whitehall criteria among subjects with normal lung function (NLF), COPD GOLD 1, 2 and 3–4, with
95 % confidence intervals. Significance is shown with **p≤ 0.01 (NLF compared with GOLD 1, 2 and 3–4, respectively). Observe that a, b and c
have different scales on the y-axis
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and non-COPD) in 2002–04. It has been described in
other COPD studies that a proportion of the study
population will transfer mainly from COPD to non-
COPD but also vice versa during follow up [37]. To ad-
dress this potential bias, data from 2005 is presented as
a straight cross-sectional analysis defining COPD and
non-COPD by current spirometry, but also by present-
ing data when the subjects had to fulfill the spirometric
criteria of either COPD or non-COPD not only in 2005
but also at baseline, i.e. at recruitment in 2002–04.
Among subjects with non-obstructive pulmonary func-
tion, also subjects with a restrictive pattern on dynamic
spirometry were included. Restrictive pattern has in pre-
vious studies been shown to associate with metabolic
disorders such as diabetes, as well as a higher prevalence
of IHD [38] or risk for cardiovascular disease [30]. Thus
we divided non-COPD into NLF and restrictive spiro-
metric pattern and compared subjects with COPD with
those having NLF.
A limitation of this study is that the self-reported bur-
den of comorbid conditions, in this study specifically is-
chemic heart disease, may be affected by recall bias as
well as misclassification since interview data were not
verified by medical records, even though literature has
shown a good agreement between self-reported diabetes,
hypertension and myocardial infarction, but not heart
failure [39]. Further, a 12-lead ECG only gives a short
glimpse of the electrical activity of the heart, and has
limited sensitivity and specificity for detecting ischemic
myocardial events. Different ischemic ECG changes, for
example ST segment changes and those involving the T-
waves, have great variations in sensitivity and specificity,
are dynamic and may thus vary over time [40, 41]. How-
ever, the strength of this epidemiological study is the large
sample size, the distribution of disease severity representa-
tive for COPD in the general population [31, 42], the use
of standardized post-broncho-dilator spirometry for defin-
ing COPD in accordance with the GOLD document [24],
and double blinded Minnesota coded ECGs. To the best
of our knowledge, this is the first population-based study
addressing ischemic heart disease among subjects with
COPD using validated and generally recommended classi-
fications of ECG-findings and COPD.
Conclusions
In this population-based study, ischemic heart disease
was equally common among subjects with COPD and
those with normal lung function. Among subjects with
COPD, there was a significant association between
higher prevalence of self-reported ischemic heart disease
and the results also indicate that there is an association
between ECG changes of ischemic heart disease and in-
creasing disease severity, as assessed by level of FEV1. A
longitudinal follow-up is important to evaluate the
prognostic value as well as progression of the observed
ECG-findings among subjects with and without COPD.
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